Clinical Outcomes of Volumetric Modulated Arc Therapy Following Intracavitary/Interstitial Brachytherapy in Cervical Cancer: A Single Institution Retrospective Experience

Purpose: To evaluate treatment outcomes and toxicity in patients with cervical cancer (CC) treated with volumetric modulated arc therapy (VMAT), followed by three-dimensional high-dose-rate intracavity combined with interstitial brachytherapy (IC/IS BT) compared with intensity-modulated radiation th...

Full description

Bibliographic Details
Main Authors: Yanzhu Lin, Yi Ouyang, Kai Chen, Zhiyuan Lu, Yonghong Liu, Xinping Cao
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-08-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00760/full
_version_ 1818853210690945024
author Yanzhu Lin
Yi Ouyang
Kai Chen
Zhiyuan Lu
Yonghong Liu
Xinping Cao
author_facet Yanzhu Lin
Yi Ouyang
Kai Chen
Zhiyuan Lu
Yonghong Liu
Xinping Cao
author_sort Yanzhu Lin
collection DOAJ
description Purpose: To evaluate treatment outcomes and toxicity in patients with cervical cancer (CC) treated with volumetric modulated arc therapy (VMAT), followed by three-dimensional high-dose-rate intracavity combined with interstitial brachytherapy (IC/IS BT) compared with intensity-modulated radiation therapy (IMRT) treatment.Materials and Methods: A total of 398 patients with stage IA–IVB CC treated with definitive radiotherapy with or without chemotherapy were retrospectively analyzed (331 VMAT and 67 IMRT). A total prescription dose of 45–50 Gy was delivered to pelvic field with VMAT/IMRT in 25/28 fractions, with five fractions per week. Every patient further received IC/IS BT for four to six 6.0-Gy fractions. Local control (LC), disease-free survival (DFS), overall survival (OS), and distant metastasis-free survival (DMFS) rates were calculated. Acute hematotoxicity and late toxicity were recorded.Results: The median follow-up period was 25.47 (range, 0.93–58.93) months for the VMAT and 35.07 (4.8–90.37) months for IMRT. The 3-year OS, DFS, LC, and DMFS rate were 80.5, 65.4, 88.7, and 78.1% in VMAT group, and 76.2, 76.4, 83.1, and 86.1% in the IMRT group, respectively. No significant differences were found between VMAT and IMRT groups for OS, DFS, LC, and DMFS rate. However, patients in the VMAT group had lower incidence of chronic enterocolitis complication (26.6 vs. 38.8%, p = 0.004). In addition, a total of 3 (0.9%) patients developed grade 3 chronic cystitis, and 7 (2.1%) patients developed grade 3 or greater chronic enterocolitis in VMAT group.Conclusion: VMAT combined with IC/IS BT can result in satisfactory curative outcomes and low incidences of late radiation enterocolitis and cystitis in CC treatment.
first_indexed 2024-12-19T07:33:12Z
format Article
id doaj.art-1e45d50173a04b4881855086d469aa46
institution Directory Open Access Journal
issn 2234-943X
language English
last_indexed 2024-12-19T07:33:12Z
publishDate 2019-08-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj.art-1e45d50173a04b4881855086d469aa462022-12-21T20:30:38ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2019-08-01910.3389/fonc.2019.00760467312Clinical Outcomes of Volumetric Modulated Arc Therapy Following Intracavitary/Interstitial Brachytherapy in Cervical Cancer: A Single Institution Retrospective ExperienceYanzhu Lin0Yi Ouyang1Kai Chen2Zhiyuan Lu3Yonghong Liu4Xinping Cao5State Key Laboratory of Oncology in South China, Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Oral and Maxillofacial Surgery, Stomatology Medical Center, Guangzhou Women and Children's Medical Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaPurpose: To evaluate treatment outcomes and toxicity in patients with cervical cancer (CC) treated with volumetric modulated arc therapy (VMAT), followed by three-dimensional high-dose-rate intracavity combined with interstitial brachytherapy (IC/IS BT) compared with intensity-modulated radiation therapy (IMRT) treatment.Materials and Methods: A total of 398 patients with stage IA–IVB CC treated with definitive radiotherapy with or without chemotherapy were retrospectively analyzed (331 VMAT and 67 IMRT). A total prescription dose of 45–50 Gy was delivered to pelvic field with VMAT/IMRT in 25/28 fractions, with five fractions per week. Every patient further received IC/IS BT for four to six 6.0-Gy fractions. Local control (LC), disease-free survival (DFS), overall survival (OS), and distant metastasis-free survival (DMFS) rates were calculated. Acute hematotoxicity and late toxicity were recorded.Results: The median follow-up period was 25.47 (range, 0.93–58.93) months for the VMAT and 35.07 (4.8–90.37) months for IMRT. The 3-year OS, DFS, LC, and DMFS rate were 80.5, 65.4, 88.7, and 78.1% in VMAT group, and 76.2, 76.4, 83.1, and 86.1% in the IMRT group, respectively. No significant differences were found between VMAT and IMRT groups for OS, DFS, LC, and DMFS rate. However, patients in the VMAT group had lower incidence of chronic enterocolitis complication (26.6 vs. 38.8%, p = 0.004). In addition, a total of 3 (0.9%) patients developed grade 3 chronic cystitis, and 7 (2.1%) patients developed grade 3 or greater chronic enterocolitis in VMAT group.Conclusion: VMAT combined with IC/IS BT can result in satisfactory curative outcomes and low incidences of late radiation enterocolitis and cystitis in CC treatment.https://www.frontiersin.org/article/10.3389/fonc.2019.00760/fullcervical cancervolumetric modulated arc therapybrachytherapytoxicityradiotherapy
spellingShingle Yanzhu Lin
Yi Ouyang
Kai Chen
Zhiyuan Lu
Yonghong Liu
Xinping Cao
Clinical Outcomes of Volumetric Modulated Arc Therapy Following Intracavitary/Interstitial Brachytherapy in Cervical Cancer: A Single Institution Retrospective Experience
Frontiers in Oncology
cervical cancer
volumetric modulated arc therapy
brachytherapy
toxicity
radiotherapy
title Clinical Outcomes of Volumetric Modulated Arc Therapy Following Intracavitary/Interstitial Brachytherapy in Cervical Cancer: A Single Institution Retrospective Experience
title_full Clinical Outcomes of Volumetric Modulated Arc Therapy Following Intracavitary/Interstitial Brachytherapy in Cervical Cancer: A Single Institution Retrospective Experience
title_fullStr Clinical Outcomes of Volumetric Modulated Arc Therapy Following Intracavitary/Interstitial Brachytherapy in Cervical Cancer: A Single Institution Retrospective Experience
title_full_unstemmed Clinical Outcomes of Volumetric Modulated Arc Therapy Following Intracavitary/Interstitial Brachytherapy in Cervical Cancer: A Single Institution Retrospective Experience
title_short Clinical Outcomes of Volumetric Modulated Arc Therapy Following Intracavitary/Interstitial Brachytherapy in Cervical Cancer: A Single Institution Retrospective Experience
title_sort clinical outcomes of volumetric modulated arc therapy following intracavitary interstitial brachytherapy in cervical cancer a single institution retrospective experience
topic cervical cancer
volumetric modulated arc therapy
brachytherapy
toxicity
radiotherapy
url https://www.frontiersin.org/article/10.3389/fonc.2019.00760/full
work_keys_str_mv AT yanzhulin clinicaloutcomesofvolumetricmodulatedarctherapyfollowingintracavitaryinterstitialbrachytherapyincervicalcancerasingleinstitutionretrospectiveexperience
AT yiouyang clinicaloutcomesofvolumetricmodulatedarctherapyfollowingintracavitaryinterstitialbrachytherapyincervicalcancerasingleinstitutionretrospectiveexperience
AT kaichen clinicaloutcomesofvolumetricmodulatedarctherapyfollowingintracavitaryinterstitialbrachytherapyincervicalcancerasingleinstitutionretrospectiveexperience
AT zhiyuanlu clinicaloutcomesofvolumetricmodulatedarctherapyfollowingintracavitaryinterstitialbrachytherapyincervicalcancerasingleinstitutionretrospectiveexperience
AT yonghongliu clinicaloutcomesofvolumetricmodulatedarctherapyfollowingintracavitaryinterstitialbrachytherapyincervicalcancerasingleinstitutionretrospectiveexperience
AT xinpingcao clinicaloutcomesofvolumetricmodulatedarctherapyfollowingintracavitaryinterstitialbrachytherapyincervicalcancerasingleinstitutionretrospectiveexperience